SPOTLIGHT: Here comes the $100B barrier


A recent conference in Philadelphia included some bold projections for biotech as the industry approaches the $100 billion mark for collective revenue. That's up from $10 billion in 1998. Keith Brownlie from Ernst & Young also notes that we're well past the point where Amgen and Genentech dominated the biotech field. Other companies like Celgene and ImClone have made an impact and more biotechs are expected to join the ranks of the Big Leagues in coming years. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.